Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 738029

TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor


Flego, Veljko; Milevoj-Ribić, Flavija; Kurpis, Marina; Barković, Igor; Matanić Lender, Dubravka; Bulat-Kardum, Ljiljana; Radojčić Badovinac, Anđelka.
TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor // ZBORNIK RADOVA / Hrvatsko torakalno društvo (ur.).
Zagreb: Hrvatsko torakalno društvo, 2012. str. 24-24 (poster, domaća recenzija, sažetak, znanstveni)


CROSBI ID: 738029 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor

Autori
Flego, Veljko ; Milevoj-Ribić, Flavija ; Kurpis, Marina ; Barković, Igor ; Matanić Lender, Dubravka ; Bulat-Kardum, Ljiljana ; Radojčić Badovinac, Anđelka.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
ZBORNIK RADOVA / Hrvatsko torakalno društvo - Zagreb : Hrvatsko torakalno društvo, 2012, 24-24

Skup
TORAKS 2012 kongres Hrvatskog torakalnog društva s međunarodnim sudjelovanjem

Mjesto i datum
Zagreb, Hrvatska, 20.09.2012. - 23.09.2012

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
TNF; polymorphisms; lung cancer; second primary tumor

Sažetak
Objective: There is no evidence that primary lung cancer is different from a second primary lung cancer (SPLC). This study attemps to determine whether SPLCs are different from sporadic cancers in clinical as well in genetic features. The purpose was quantitative evaluation of the association between TNF-α gene polymorphism at site -308 and -238 and lung cancer as a second primary cancer susceptibility. Method: 104 patients with SPLC, 98 non-small cell lung cancer (NSCLC) and 6 small cell lung cancer (SCLC), were investigated. 201 unrelated first primary lung cancer patients, 174 NSCLC and 27 SCLC, were taken as control subjects. TNF-α-308 and TNF-α-238 polymorphisms were investigated in both test group. Results: 70 patients were male and 34 were female. The average age of control group patients was 59.4 years, and SPLC was 68.3 years. Disease free interval (DFI) between first tumor and SPLC was 9.2 years in average. In this, the difference between males and females was significant (6.7 versus 13.5 years ; p<0.001). We did not find any association between particular genotypes and DFI. There was no statistically significant difference between distribution of TNF-α-308 polymorphism genotype and the allele between lung cancer patients with first primary and second primary carcinoma. However, the distribution of TNF-α-238 polymorphism GG genotype and the G allele in SPLC in relation to first primary lung cancer was almost statistically significantly higher (p=0.054 and p=0.057, respectively). The group of second primary NSCLC in relation to first primary NSCLC had more frequent TNF-α-238 polymorphism GG genotype (the difference approached statistical significance, p=0.060) and the G allele (the difference approached statistical significance, p=0.064). When comparing second primary SCLC and first primary SCLC there was no statistically significant difference in distribution of TNF-α-238 polymorphism GG genotype and the G allele. All 104 patients with SPLC had TNF-α-238 GG genotype and the G allele. Conclusion: Cancer free interval between the tumors was significantly longer in females. Second primary NSCLC in relation to first primary NSCLC had more frequent TNF-α-238 polymorphism GG genotype and the G allele. TNF-α-238 GG genotype could have a promotive effect for SPLC, particularly for NSCLC.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka


Citiraj ovu publikaciju:

Flego, Veljko; Milevoj-Ribić, Flavija; Kurpis, Marina; Barković, Igor; Matanić Lender, Dubravka; Bulat-Kardum, Ljiljana; Radojčić Badovinac, Anđelka.
TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor // ZBORNIK RADOVA / Hrvatsko torakalno društvo (ur.).
Zagreb: Hrvatsko torakalno društvo, 2012. str. 24-24 (poster, domaća recenzija, sažetak, znanstveni)
Flego, V., Milevoj-Ribić, F., Kurpis, M., Barković, I., Matanić Lender, D., Bulat-Kardum, L. & Radojčić Badovinac, A. (2012) TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor. U: Hrvatsko torakalno društvo (ur.)ZBORNIK RADOVA.
@article{article, author = {Flego, Veljko and Milevoj-Ribi\'{c}, Flavija and Kurpis, Marina and Barkovi\'{c}, Igor and Matani\'{c} Lender, Dubravka and Bulat-Kardum, Ljiljana and Radoj\v{c}i\'{c} Badovinac, An\djelka.}, year = {2012}, pages = {24-24}, keywords = {TNF, polymorphisms, lung cancer, second primary tumor}, title = {TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor}, keyword = {TNF, polymorphisms, lung cancer, second primary tumor}, publisher = {Hrvatsko torakalno dru\v{s}tvo}, publisherplace = {Zagreb, Hrvatska} }
@article{article, author = {Flego, Veljko and Milevoj-Ribi\'{c}, Flavija and Kurpis, Marina and Barkovi\'{c}, Igor and Matani\'{c} Lender, Dubravka and Bulat-Kardum, Ljiljana and Radoj\v{c}i\'{c} Badovinac, An\djelka.}, year = {2012}, pages = {24-24}, keywords = {TNF, polymorphisms, lung cancer, second primary tumor}, title = {TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor}, keyword = {TNF, polymorphisms, lung cancer, second primary tumor}, publisher = {Hrvatsko torakalno dru\v{s}tvo}, publisherplace = {Zagreb, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font